Jeil Pharmaceutical Co Ltd

Jeil Pharmaceutical Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.44, below the median for the Pharmaceuticals industry, indicating a relatively low reliance on debt financing. The company's liquidity position is mixed, with a current ratio of 1.29 and negative net cash after subtracting total debt, suggesting potential short-term liquidity constraints. Profitability metrics show a return on equity (ROE) of 11.08% and a return on assets (ROA) of 4.58%, both above the industry median for Pharmaceuticals, indicating strong asset utilization and profitability relative to peers. The company's gross margin of 37.5% (calculated from gross profit and revenue) is in line with industry norms, but its operating margin of 3.65% is slightly below the median, suggesting potential cost pressures or competitive pricing dynamics. Geographically, Jeil Pharmaceutical Co Ltd is heavily concentrated in the domestic South Korean market, with no disclosed revenue breakdown for overseas operations. This concentration may expose the company to regulatory and economic risks specific to the Korean market, though the lack of segment data prevents a more granular assessment. The company's growth trajectory is modest, with no disclosed revenue growth rates in the input data. Free cash flow of 37.24 billion KRW supports operational flexibility, but capital expenditures of -9.08 billion KRW suggest a focus on cost optimization rather than expansion. The absence of forward-looking guidance in the input data limits the ability to assess long-term growth potential. Risk factors include a medium liquidity risk due to negative net cash and a current ratio near the threshold of 1.0. The company's dilution risk is low, with no dilutive shares outstanding and no recent equity issuance activity. However, the absence of disclosed dilution sources in the input data means this assessment is based on the current capital structure. Recent events include no disclosed filings or transcripts in the input data, so no specific developments can be cited. The company's financial snapshot is based on the latest available data from HA-market data, with no additional commentary on recent strategic or operational changes.